SEC filing · 10-K

Propanc Biopharma, Inc.: Annual report

Propanc Biopharma reported no revenue and a net loss of $18,862,710 for fiscal year 2026 amid ongoing going concern warnings.

Filed September 25, 2026 · period ended June 30, 2026

Negative for the company

What the numbers say

Diluted EPS -$17.62 versus -$371.22; operating cash flow -$5.7M (a year earlier -$405.2K); free cash flow -$5.7M; cash rose by $819.9K to $832K; diluted share count up 608% (dilution).

Compared with the same period a year earlier, from the figures Propanc Biopharma, Inc. reported to the SEC.

What happened

The company generated no revenue in fiscal year 2026 as it remains in the research and development stage.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Propanc Biopharma, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.